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Abstract
Introduction: Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a
subtype of T-ALL and its clinical entity was established in recent years based on
characteristic immunophenotyping and gene expression profiles. The cellular origin
of ETP-ALL is supposed to be from common hematopoietic progenitors both for
lymphoid and myeloid lineages because this leukemia phenotypically exhibits
lymphoid, myeloid, and stem cell features. ETP-ALL comprises 5–15% of all T-ALL
and is associated with a poor prognosis. The purpose of this chapter is to clarify the
etiology, clinical picture, and therapeutic strategy of ETP-ALL showing two cases of
this leukemia in our institution.
Cellular origin of ETP-ALL: The normal early T-cell precursors (ETPs) are considered
to be a subset of early thymocytes which are originated from the bone marrow and
subsequently reside in the thymus, retaining multilineage differentiation potential as
the common lymphoid-myeloid hematopoietic progenitors. ETP-ALL is supposed to
be a neoplastic counterpart of ETPs.
Immunophenotype and diagnosis of ETP-ALL: ETP-ALL is characterized by the lack
of expression of T-lineage cell surface antigens (CD1a and CD8, weak or no expression
of CD5) and expression of myeloid and hematopoietic stem cell markers such as CD13,
CD33, CD34, and CD117. These characteristic immunophenotypic profiles have
provided a scoring system or a criterion for the diagnosis of ETP-ALL, which
distinguishes ETP-ALL from classical T-ALL.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Clinical pictures: Clinical features are not substantially different between ETP-ALL
and classical T-ALL, although ETP-ALL is associated with a higher rate of relapse and
induction failure and a significantly worse overall survival. Two cases of ETP-ALL in
our institution, which exhibited unique clinical pictures, that is, marked intestinal
involvement and lymphoma-like systemic lymphadenopathy, respectively, will be
discussed later in this chapter.
Gene profiles: Whole-genome sequencing studies on ETP-ALL have demonstrated
several recurrent mutations involving genes coding cytokines, RAS signaling
mediators (NRAS, KRAS, FLT3, IL7R, JAK3, LAK1, SH2B3, and BRAF), epigenetic
controllers (EZH2, EED, SUZ12, SETD2, EP300 and DNMT3A), and hematopoietic
transcriptional regulators (GATA3, ETV6, RUNX1, IKZF1, and EP300). These
mutational spectrums are similar to those of acute myeloid leukemia.
Therapeutic strategies: These gene profiles suggest that treatment of ETP-ALL may
benefit from a new chemotherapeutic approach, which is directed to the myeloid or
stem cell natures of this leukemia, such as high-dose cytarabine, or epigenetic or
molecular targeting therapy. Allogeneic stem cell transplantation (allo-SCT) may be
a promising option for the treatment of ETP-ALL.
Conclusion: More precise and extensive cellular and molecular investigations are
required to establish definite cellular origin and genetic or epigenetic nature of ETP-
ALL. Accumulation of ETP-ALL cases and larger clinical trials will establish an
effective therapeutic strategy for this high risk leukemia.
Keywords: Early T-cell precursor acute lymphoblastic leukemia
1. Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is a clonal malignant disorder of immature T-
cells that accounts for 10–15% of childhood and 25% of adult ALL patients [1]. Despite the
relatively high morbidity and mortality of T-ALL when compared to B-cell ALL, the prognosis
of T-ALL has dramatically improved following the advancement of chemotherapy, and its
long-term survival has become as high as 85% in both pediatric and adult T-ALL patients [2,
3]. However, a refractory subset of pediatric T-ALL associated with a poor prognosis has
remained. In 2009, a study performed at St. Jude Children’s Research Hospital identified a
distinct subtype of pediatric T-ALL, which was designated as early T-cell precursor ALL (ETP-
ALL) [4]. This new subtype of T-ALL was defined according to the characteristic gene
expression profile and immunophenotypes of the leukemic cells and was found to be associ‐
ated with a high rate of remission induction failure or relapse when the patients were treated
with conventional chemotherapy [4].
The purpose of this chapter is to clarify the recent advances in the biology, genetics, clinical
characteristics, and therapeutic strategy of ETP-ALL and discuss two cases experienced at our
institution.
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2. Cellular origin of ETP-ALL
Normal early T-cell precursors (ETPs) are a subset of thymocytes, which have newly immi‐
grated from the bone marrow to the thymus, and they retain multilineage differentiation
potential, suggesting their direct derivation from hematopoietic stem cells [5-7]. The initial
stage of thymocyte development is characterized by the generation of cells that lack the
expression of CD4 or CD8 antigen. Along with the differentiation of these double negative
cells, a minimum of four distinct differentiation stages have been identified according to the
differential expressions of CD44 and CD25, that is, DN1, DN2, DN3, and DN4 stages. The
potential for myeloid, dendritic, and natural killer cell differentiation is retained at both the
DN1 and early DN2 stages [6]. The ability to confer multilineage differentiation is lost at the
DN3 stage, and provably, at the latter half of DN2 progression [8]. Therefore, it may be
reasonable that the tumor-initiating cells in ETP-ALL could originate from DN1 and/or DN2
thymocytes (Figure 1). However, in recent years, a mouse model of T-ALL using a Sleeping-
Beauty-based transposon system suggested that ETP-ALL may be derived from more mature
T-cells [9]. Thus, the exact cellular origin of ETP-ALL remains to be elucidated.
Figure 1. Early T-cell development and supposed cellular origin of ETP-ALL.
3. Immunophenotyping and diagnosis of ETP-ALL
Immunophenotyping of ETP-ALL cells is characterized by the lack of CD1a and CD8 expres‐
sions, weak CD5 expression (< 75% positive blasts), and the expression of one or more of the
following myeloid or stem cell antigens on at least 25% of the leukemic cells: CD117, CD34,
HLA-DR, CD13, CD33, CD11b, and/or CD65 [4]. Subsequently, a study proposed a scoring
system based on the expression of commonly available eleven markers: CD5, CD8, CD13,
CD33, CD34, HLA-DR, CD2, smCD3, CD4, CD10, and CD56 (Figure 2A) [10]. The specificity
and sensitivity of this scoring system were 100% and 94%, respectively, when applied to the
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patients in the St. Jude cohort (Figure 2B) [10]. Recently, another study attempted to make a
more simple diagnosis of ETP-ALL using the expression of CD5 and concluded that CD5-
negative T-ALL could be diagnosed as ETP-ALL because CD5 negativity was associated with
positive myeloid/stem cell antigens but not CD1a and CD8 expressions (Figure 3) [11].
Currently, precise immunophenotyping is the most important tool to make a diagnosis of ETP-
ALL, and this analysis enables us to distinguish ETP-ALL from classical T-ALL.
Figure 2. A scoring system for immunophenotypical diagnosis of ETP-ALL. A: Scoring system based on the expression
of 11 markers., B: Distribution of total score of 11-marker expression in ETP-ALL patients (right) and T-ALL (left) of
the St Jude cohort. (Extract of Ref.10).
4. Clinical characteristics
Following the early reports from the St. Jude Children’s Research Hospital and the Associa‐
zione Italiana Ematologica Oncologica Pediatrica (AIEOP), comparative studies on the clinical
characteristics between ETP-ALL and classical T-ALL were performed in six institutions: the
Tokyo Children’s Cancer Study Group [10], the Shanghai Children’s Medical Center [12], the
German Multicenter Study Group for adult ALL [13], Colombia University Medical Center
[14], All India Institute of Medical Sciences [11], and the Medical Research Council UK-ALL
2003 trial [15] (Table 1). According to the results of these clinical studies, ETP-ALL was
observed to comprise 5.5–16% of all T-ALL cases. The clinical characteristics were similar
between ETP-ALL and classical T-ALL with regard to gender, hemoglobin concentration, and
central nervous system involvement. However, ETP-ALL patients presented with a lower
white blood cell (WBC) count [11, 12, 15], lower frequency of the mediastinal mass [13, 14],
and higher age (10 years or older) [4, 11] at presentation when compared to those with classical
T-ALL. Regarding the cytogenetic profile, Coustan-Smith et al. reported that ETP-ALL had
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more 13q- and DNA copy number abnormalities than those in classical T-ALL [4]. Conversely,
Allen et al. reported that the majority of patients with ETP-ALL exhibited a normal karyotype
without recurrent cytogenetic abnormalities [14]. The monoclonal rearrangement of T-cell
receptor genes was observed in 71% of the ETP-ALL cases, showing no significant difference
between the two T-ALL subgroups [14].
Table 1. Comparative studies on the clinical characteristics between ETP-ALL and classical T-ALL.
Figure 3. A flowchart for the diagnosis of ETP-ALL based on CD5 expression (Extract of Ref.11).
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As for the prognosis, ETP-ALL is associated with a higher rate of relapse and induction failure.
ETP-ALL is additionally associated with a significantly worse overall survival with a 10-year
event free survival (EFS) and overall survival (OS) rates of 22% and 19%, respectively, as
compared with 69% EFS and 84% OS for all other subtypes of T-ALL, respectively, in the St.
Jude cohort [4]. Similar results were obtained in the cohorts of four other institutions [4, 10-12].
More recently, however, two clinical studies showed no significant differences in the EFS and
OS rates between the patients with ETP-ALL and classical T-ALL [14, 15]. Although the reason
for this discrepancy is unclear, differences in the therapeutic protocol and patient cohort may
have influenced the results of these clinical studies. However, an increased risk of relapse in
the patients with ETP-ALL [4, 10-12, 15], especially children [4, 14], was a common result in
all these previous studies. Thus, larger prospective studies are needed to determine the real
prognosis of this T-ALL subtype.
5. Gene profiles
The expression levels of oncogenic transcription factor genes were examined to establish
genetic profiles of ETP-ALL in the St Jude Children’s Research Hospital and AIEOP studies.
Pediatric ETP-ALL had a higher expression of oncogenic transcription factors: LMO1, LMO2,
LYL1, and ERG [4, 16]. LMO1 and LMO2 are binding partners with hematopoietic basic helix-
loop-helix transcription factors, such as SCL/TAL1 or LYL1. These proteins interact together to
form a transcription factor complex, and they are hypothesized to act through a common
mechanism which leads to oncogenesis of T-ALL [17]. McCormack et al. demonstrated that
LYL1 is critical for the oncogenic function of LMO2, including the upregulation of a stem cell-
like gene signature, aberrant self-renewal of thymocytes, and subsequent generation of T-cell
leukemia in LMO2-transgenic mice. Moreover, LMO2 and LYL1 are co-expressed in leukemic
cells from the patients with ETP-ALL, and LYL1 is indispensable for the growth of ETP-ALL
cell lines [18]. Whole-genome sequencing studies showed that ETP-ALL had a high frequency
of activating mutations in the genes involved in cytokine receptor and RAS signaling (e.g.,
NRAS, KRAS, FLT3, IL-7R, JAK3, LAK1, SH2B3, and BRAF) and inactivating mutations in the
genes encoding key transcription factors involved in hematopoietic development (e.g.,
GATA3, ETV6, RUNX1, IKZF1, and EP300) and involved in epigenetic gene control (e.g., EZH2,
EED, SUZ12, SETD2, and EP300 genes) [16]. The gene mutations which affect cytokine receptor
regulation and/or RAS signaling pathway are observed in two-thirds of ETP-ALL cases but
only in 19% of non-ETP T-ALL cases [16]. These mutational gene spectrums in ETP-ALL are
similar to those in acute myeloid leukemia (AML), but not in T- or B-lineage ALLs. Further‐
more, the global transcriptional profile of ETP-ALL is similar to that of normal hematopoietic
stem cells, AML stem cells, and murine ETP. The activating mutations in the interleukin-7
receptor (IL-7R) gene were reported to be sufficient to generate ETP-ALL in mice, and this
murine ETP-ALL model showed the blockage of thymocyte differentiation at the DN2 stage,
at which the developmental potentials for both myeloid and T-cell lineages coexists [19]. These
findings suggesting ETP-ALL is a neoplasm at the stage of less mature hematopoietic progen‐
itor or stem cells may account for the capacity of ETP-ALL to exert myeloid differentiation.
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Gene expression profiling was also investigated in adult ETP-ALL patients. Whole-exome
sequencing in adult ETP-ALL cells demonstrated a distinct mutation spectrum from that of
pediatric ETP-ALL, particularly in affecting genes involved in epigenetic regulation with
higher frequencies of DNMT3A and FAT3 mutations [20]. DNMT3A, one of the genes for DNA-
methyl-transferase, is a frequent mutational target in AML [21], whereas FAT3 mutations have
been frequently reported in ovarian carcinomas but not AML [22]. The incidence of DNMT3A
mutations showed a clear age relationship [20]. Adult ETP-ALL patients also had mutations
in the genes known to be involved in leukemogenesis, including ETV6, NOTCH1, JAK1, and
NF1. In addition, more than 60% of the adult patients with ETP-ALL harbored at least a single
genetic lesion in DNMT3A, FLT3, or NOTCH1 [20]. Furthermore, adult ETP-ALL showed
higher expression levels of BAALC, IGFBP7, WT-1, and MN1 than those in classical T-ALL [4,
13, 18]. As described above, the high expression of BAALC and ERG were predictive for
unfavorable outcomes in adult T-ALL [23, 24]. IGFBP7 is a stem cell-associated gene, which is
functionally highly related to BAALC and overexpressed in early T-ALL [25]. The WT-1 gene
is commonly overexpressed in AML [26], and its overexpression is associated with a poor
prognosis in thymic T-ALL patients [27]. The overexpression of the MN1 gene is additionally
associated with a shorter survival in the patients with AML without karyotypic abnormalities
[28, 29]. The FLT3 mutations which are frequently observed in AML were found in 37.5% of
the adult ETP-ALL but only in 1–3% of the classical T-ALL patients (37.5%) [13], although these
FLT3 mutations in ETP-ALL more frequently generated tyrosine kinase domain (TDK)
abnormalities rather than internal tandem duplication (ITD) mutations, which are frequently
observed in AML. In relation to the above-mentioned observations, mice that received a
transplant of FLT3-ITD-transduced bone marrow cells developed myeloproliferative diseases,
while those that received a transplant of FLT3-TDK-transduced bone marrow cells developed
lymphoid disorders [30]. Collectively, it may be reasonable to separate ETP-ALL from classical
T-ALL due to the distinct genetic profiles between ETP-ALL and other T-ALL subtypes, and
the characteristic gene profile of ETP-ALL may provide new therapeutic strategies for this
leukemia.
6. Therapeutic strategies
Coustan-Smith et al. previously reported that the patients with ETP-ALL showed a poor initial
response to standard intensive chemotherapies and unfavorable outcomes [4]. Subsequently,
six clinical studies showed that ETP-ALL was associated with a very high risk for relapse,
whereas two additional studies showed no significant differences in both the EFS and OS rates
between the patients with ETP-ALL and classical T-ALL [14, 15]. In the TLLSGL99-15 study,
three of four relapsed ETP-ALL patients were successfully treated with allogenic hemato‐
poietic stem cell transplantation (allo-SCT), indicating that allo-SCT could be an effective
therapeutic option for ETP-ALL [10]. Prior to this report, the Berlin-Frankfurt-Munster group
showed that allo-SCT was superior to chemotherapy alone for high-risk childhood T-ALL [31].
The UKALL 2003 study, which showed better outcomes of ETP-ALL, suggested the beneficial
effects of a more intensive chemotherapeutic regimen and the employment of dexamethasone
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and pegylated asparaginase [15]. High-dose cytarabine combined with epigenetic treatment
may be a promising option for ETP-ALL according to the results of whole-genome sequencing,
which showed that the mutational spectrum of ETP-ALL was similar to that of AML and that
the transcriptional profile was similar to that of normal hematopoietic stem cells and granu‐
locyte-macrophage progenitor cells [4], although these hypotheses need to be proven in future
investigations. Additionally, other potential targets have been suggested according to the
genetic alterations in the transcription factors. Stat4 phosphorylation was observed in IL-7R
mutant-induced ETP-ALL cell lines, and consequently, ruxolitinib which is a selective JAK1
and JAK2 inhibitor, was shown to inhibit the proliferation of cells from the ETP-ALL cell lines
and prolong the survival of mice xeno-transplanted with the IL-7R mutated ETP-ALL cells [19].
Tyrosine kinase inhibitors may be effective when FLT3 mutations harboring ETP-ALL are
molecularly targeted [13]. The antiapoptotic B-cell lymphoma-2 (BCL-2) protein is another
attractive molecular target. BCL-2 is highly expressed in ETP-ALL and gradually decreases its
expression along with the differentiation toward mature T-cells. ABT-199, an orally bioavail‐
able BCL-2 specific inhibitor, was demonstrated to induce apoptosis of ETP-ALL cells from
patients with this subtype of leukemia and dramatically reduced the tumor burden in the bone
marrow, spleen, and peripheral blood in mice transplanted with ETP-ALL patient-derived
xenografts [32, 33]. In addition, a WT-1 peptide cancer vaccine may be a therapeutic option for
relapsed patients or those with minimal residual disease in WT-1-overexpressed ETP-ALL,
because this approach has demonstrated objective clinical responses in other hematological
neoplasms and solid tumors [34].
7. Case study
For a better understanding of ETP-ALL, we herein present two cases of ETP-ALL in our
institution, which exhibited unique clinical pictures.
Case 1: A 24-year-old man developed epigastralgia and low-grade fever four months before
the admission to our hospital. On gastrofiberscopy performed in a hospital, multiple non-
ulcerative mucosal nodules were observed. A biopsy specimen from the nodule histologically
showed diffuse infiltration of small lymphocytes, which were positive for CD3, CD7, CD8, and
CD56 but negative for TIA-1, Epstein-Barr virus-encoded small RNAs-in situ hybridization
(EBER-ISH), and a suspected pathological diagnosis was lymphomatoid gastroenteropathy.
Three months later, the patient was admitted to our hospital due to the exacerbation of
abdominal distress. On this admission, he presented with multiple ulcerative nodules in the
gastric mucosa (Figure 4), marked wall thickening of the small intestine, hepatosplenomegaly
(Figure 5) and multiple nodular lesions in the bilateral lungs. A histological examination of
the biopsied gastric mucosal nodule showed dense infiltration with small immature lympho‐
cytes (Figure 6). The WBC count elevated to 3.83×109/L with 55% immature lymphocytes
(Figure 7). Flow cytometry indicated that these cells were positive for cyCD3, CD7, CD8, CD13,
and CD56 (partially), but negative for CD2, smCD3, CD34, TdT, B-cell antigens, and cytoplas‐
mic myeloperoxidase (MPO). A multiplex PCR analysis for TCRγ chain and immunoglobulin
heavy chain genes yielded negative results regarding the monoclonal gene rearrangements. A
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cytogenetic examination of the bone marrow cells, including abundant leukemic cells, gave a
normal karyotype of 46, XY. He was subsequently diagnosed with ETP-ALL according to these
immunophenotypes of abnormal lymphocytes, which fulfilled the criteria of the TCCSG
L99-15 study scoring system but not the St. Jude Criteria due to the CD8 positivity. Although
the leukemia was resistant to CHOP (cyclophosphamide, adriamycin, vincristine, and
prednisolone) and SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and
etoposide) [35] regimens, a complete remission (CR) was obtained with the MEC regimen
(mitoxantrone, etoposide, and cytarabine) followed by nelarabine. He underwent unrelated
allogeneic bone marrow transplantation and is currently maintaining CR. Importantly, a
marked intestinal involvement at presentation has not been reported in ETP-ALL.
Figure 4. Gastrofiberscopy of Case 1 on admission to our hospital. Multiple ulcerative nodules were visible on the gas‐
tric mucosa.
Case  2:  An  83-year-old  female  who  presented  with  generalized  lymphadenopathy  was
referred to our hospital. She was tentatively diagnosed with peripheral T-cell lymphoma-
unspecified according to the findings from a biopsy specimen from a cervical lymph node,
which  histologically  showed  diffuse  infiltration  of  CD3-positive  lymphocytes  and  a
proliferation  of  Langerhans  cells  without  dysplastic  features.  The  lymphadenopathy
disappeared after CHOP chemotherapy; however, blast cells (Figure 8A) appeared in the
peripheral blood and rapidly increased in number without recurrence of the lymphadenop‐
athy after the fourth round of CHOP chemotherapy. The blast cells expressed cyCD3, CD7,
CD56, CD33, and CD34, but not CD2, smCD3, CD4, and CD8. PCR of the TCRγ chain gene
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demonstrated a monoclonally rearranged faint  band.  These blast  cells  were negative for
MPO staining; however, some of the cells were weakly positive for both α-naphthyl butyrate
(Figure 8B) and naphthol AS-D chloroacetate esterase staining (Figure 8C), suggesting their
ability  to  differentiate  toward  monocytes  and  granulocytes.  A  chromosomal  analysis
revealed  an  abnormal  karyotype  of  46,  XX,  t(12;20)(q13;q11.2)  in  seven  of  the  20  bone
marrow  cells  analyzed.  A  final  diagnosis  of  ETP-ALL  was  made  according  to  these
immunophenotypes, which fulfilled both the TCCSG L99-15 study scoring system and St.
Jude criteria. Her leukemia was resistant to any chemotherapeutic protocols for lympho‐
ma, ALL, and AML, and she ultimately died due to disease progression.
Figure 5. Contrast CT scanning of the abdomen (coronal image) in Case 1. Marked hepatosplenomegaly and wall
thickening of the small intestine (arrows) were observed.
Figure 6. Histology of the biopsied gastric mucosal nodule in Case 1. Diffuse and dense infiltration of immature lym‐
phocytes is shown (H-E staining, 100×).
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 Figure 8. Abnormal lymphocytes in the peripheral blood in Case 2. A: Wright-Giemsa staining, 1,000×); B: a-naphthyl
butyrate esterase staining; C: naphthol AS-D chloroacetate esterase staining. Esterase staining was performed using a
kit for double esterase staining (Muto Pure Chemicals, Tokyo, Japan).
In both cases, it was difficult to make a precise diagnosis with a histopathological strategy, and
the immunophenotypic analysis was crucially important to determine the final diagnosis. Both
cases are very interesting in terms of the phenotypic presentation reflecting an oncogenic
development at the level of granulocyte-macrophage-T-cell progenitors in early normal
hematopoiesis. In addition, morphologically, leukemic cells in these two cases had a slightly
condensed chromatin network of the nucleus when compared with that of classical ALL blasts
and these nuclei were irregular in shape.
8. Conclusion
More precise and extensive cellular and molecular investigations are required to establish the
definite cellular origin and genetic or epigenetic nature of ETP-ALL. An accumulation of ETP-
ALL cases and larger clinical trials will establish effective therapeutic strategies for this high-
risk leukemia.
Figure 7. Abnormal lymphocytes in the peripheral blood in Case 1 (Wright-Giemsa staining, 1,000×).




Hiroko Tsunemine and Takayuki Takahashi*
*Address all correspondence to: takahashi.takayuki@shinkohp.or.jp
Department of Hematology, Shinko Hospital, Kobe, Japan
The authors declare that there are no conflicts of interest with any individuals or companies.
References
[1] Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med.
2006;354:166-78.
[2] Hoelzer D, Gokbuget N, Digel W, Faak T, Kneba M, Reutzel R, et al. Outcome of
adult patients with T-lymphoblastic lymphoma treated according to protocols for
acute lymphoblastic leukemia. Blood. 2002;99:4379-85.
[3] LeClerc JM, Billett AL, Gelber RD, Dalton V, Tarbell N, Lipton JM, et al. Treatment of
childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium
Protocol 87-01. J Clin Oncol. 2002;20:237-46.
[4] Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Ear‐
ly T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leu‐
kaemia. Lancet Oncol. 2009;10:147-56.
[5] Rothenberg EV, Moore JE, Yui MA. Launching the T-cell-lineage developmental pro‐
gramme. Nat Rev Immunol. 2008;8:9-21.
[6] Bell JJ, Bhandoola A. The earliest thymic progenitors for T cells possess myeloid line‐
age potential. Nature. 2008;452:764-7.
[7] Wada H, Masuda K, Satoh R, Kakugawa K, Ikawa T, Katsura Y, et al. Adult T-cell
progenitors retain myeloid potential. Nature. 2008;452:768-72.
[8] Yui MA, Feng N, Rothenberg EV. Fine-scale staging of T cell lineage commitment in
adult mouse thymus. J Immunol. 2010;185:284-93.
[9] Berquam-Vrieze KE, Nannapaneni K, Brett BT, Holmfeldt L, Ma J, Zagorodna O, et
al. Cell of origin strongly influences genetic selection in a mouse model of T-ALL.
Blood. 2011;118:4646-56.
[10] Inukai T, Kiyokawa N, Campana D, Coustan-Smith E, Kikuchi A, Kobayashi M, et al.
Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results
of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol.
2012;156:358-65.
Leukemias - Updates and New Insights38
[11] Chopra A, Bakhshi S, Pramanik SK, Pandey RM, Singh S, Gajendra S, et al. Immuno‐
phenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL per‐
spective of non-ETP T-ALL. Eur J Haematol. 2014;92:211-8.
[12] Ma M, Wang X, Tang J, Xue H, Chen J, Pan C, et al. Early T-cell precursor leukemia: a
subtype of high risk childhood acute lymphoblastic leukemia. Front Med.
2012;6:416-20.
[13] Neumann M, Heesch S, Gokbuget N, Schwartz S, Schlee C, Benlasfer O, et al. Clinical
and molecular characterization of early T-cell precursor leukemia: a high-risk sub‐
group in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J.
2012;2:e55.
[14] Allen A, Sireci A, Colovai A, Pinkney K, Sulis M, Bhagat G, et al. Early T-cell precur‐
sor leukemia/lymphoma in adults and children. Leuk Res. 2013;37:1027-34.
[15] Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, et al. Out‐
come for children and young people with early T-cell precursor acute lymphoblastic
leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol.
2014;166:421-4.
[16] Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic
basis of early T-cell precursor acute lymphoblastic leukaemia. Nature.
2012;481:157-63.
[17] Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and
lymphoma. Nat Rev Immunol. 2008;8:380-90.
[18] McCormack MP, Shields BJ, Jackson JT, Nasa C, Shi W, Slater NJ, et al. Requirement
for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL. Blood.
2013;122:2093-103.
[19] Treanor LM, Zhou S, Janke L, Churchman ML, Ma Z, Lu T, et al. Interleukin-7 recep‐
tor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors
with multipotent potential. J Exp Med. 2014;211:701-13.
[20] Neumann M, Heesch S, Schlee C, Schwartz S, Gokbuget N, Hoelzer D, et al. Whole-
exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.
Blood. 2013;121:4749-52.
[21] Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A
mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424-33.
[22] Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15.
[23] Baldus CD, Burmeister T, Martus P, Schwartz S, Gokbuget N, Bloomfield CD, et al.
High expression of the ETS transcription factor ERG predicts adverse outcome in
acute T-lymphoblastic leukemia in adults. J Clin Oncol. 2006;24:4714-20.
Early T-cell Precursor Acute Lymphoblastic Leukemia – A Characteristic Neoplasm Presenting the Phenotype of…
http://dx.doi.org/10.5772/60901
39
[24] Baldus CD, Martus P, Burmeister T, Schwartz S, Gokbuget N, Bloomfield CD, et al.
Low ERG and BAALC expression identifies a new subgroup of adult acute T-lym‐
phoblastic leukemia with a highly favorable outcome. J Clin Oncol. 2007;25:3739-45.
[25] Heesch S, Schlee C, Neumann M, Stroux A, Kuhnl A, Schwartz S, et al. BAALC-asso‐
ciated gene expression profiles define IGFBP7 as a novel molecular marker in acute
leukemia. Leukemia. 2010;24:1429-36.
[26] Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, et al. Presence of
Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of
human acute leukemias. Leukemia. 1995;9:1060-7.
[27] Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, Burmeister T, et al. Prog‐
nostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in
adult acute T-lymphoblastic leukemia. Haematologica. 2010;95:942-9.
[28] Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B, et al.
High meningioma 1 (MN1) expression as a predictor for poor outcome in acute mye‐
loid leukemia with normal cytogenetics. Blood. 2006;108:3898-905.
[29] Grosveld GC. MN1, a novel player in human AML. Blood Cells Mol Dis.
2007;39:336-9.
[30] Hosoya T, Kuroha T, Moriguchi T, Cummings D, Maillard I, Lim KC, et al. GATA-3
is required for early T lineage progenitor development. J Exp Med.
2009;206:2987-3000.
[31] Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, et al. Su‐
periority of allogeneic hematopoietic stem-cell transplantation compared with che‐
motherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results
from ALL-BFM 90 and 95. J Clin Oncol. 2006;24:5742-9.
[32] Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Ma‐
turation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-
XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074-87.
[33] Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, et al.
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute
lymphoblastic leukemia. Blood. 2014;124:3738-47.
[34] Van Driessche A, Berneman ZN, Van Tendeloo VF. Active specific immunotherapy
targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malig‐
nancies and solid tumors: lessons from early clinical trials. Oncologist. 2012;17:250-9.
[35] Yamaguchi M, Kwong KL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II
study of SMILE chemotherapy for newly diagnosed stage IV, relapsed or refractory
extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor
Study Group Study. J Clin Oncol. 2011;29:4410-16.
Leukemias - Updates and New Insights40
